Poor
Major Misalignment
Patient Risk:
Medium
Summary
Multiple core label elements are incorrect or unsupported versus the provided FDA label excerpts, including active ingredient identification, mechanism/dosing basis (antihistamine + corticosteroid delivery claim), indication scope (seasonal allergic rhinitis only), and adverse reaction frequency/constituent claims.
Category Scores
Accurate Statements
Ryaltris is a prescription nasal spray.
Supported by provided label context that it is for nasal use only and is a nasal spray.
Ryaltris is indicated for the treatment of nasal allergy symptoms in patients 12 years of age and older.
Label excerpt: "RYALTRIS is indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older."
The active ingredients in Ryaltris include olopatadine hydrochloride.
Label mentions olopatadine hydrochloride as an ingredient in dosing and clinical pharmacology excerpt (H1 receptor inhibitor).
Olopatadine is an H1 antihistamine.
Label excerpt (12.1): "Olopatadine is a histamine-1 (H1) receptor inhibitor."
Fluticasone propionate is a corticosteroid.
Not supported as stated because the provided label excerpt identifies mometasone furoate (not fluticasone propionate). Corticosteroid status for mometasone furoate is supported; however the named drug fluticasone is not in the provided label excerpts.
Unsupported Statements
Ryaltris received FDA approval on August 29, 2023.
No FDA approval date is included in the provided label excerpts.
Ryaltris is indicated for the relief of nasal and ocular symptoms of seasonal allergic rhinitis (SAR).
Provided indication excerpt specifies treatment of symptoms of seasonal allergic rhinitis but does not explicitly state "nasal and ocular symptoms."
Ryaltris is indicated for the relief of nasal and ocular symptoms of perennial allergic rhinitis (PAR).
Provided label excerpts state indication for seasonal allergic rhinitis only; no perennial allergic rhinitis indication is provided.
Ryaltris is a prescription nasal spray that combines the antihistamine olopatadine and the corticosteroid fluticasone propionate.
Provided label excerpts identify mometasone furoate (not fluticasone propionate) as the corticosteroid ingredient; thus the specific combination as stated is not supported.
The active ingredients in Ryaltris are olopatadine hydrochloride and fluticasone propionate.
Provided label excerpts list olopatadine hydrochloride and mometasone furoate (not fluticasone propionate).
Olopatadine blocks the action of histamine, a substance that causes allergic symptoms.
The label excerpt supports H1 receptor inhibition but does not include the statement that it "blocks the action of histamine" nor that histamine is described as "a substance that causes allergic symptoms."
Fluticasone propionate reduces inflammation associated with allergies.
The label excerpt supports anti-inflammatory activity for mometasone furoate, but does not mention fluticasone propionate or use the phrasing about "associated with allergies."
Ryaltris works by delivering a combination of an antihistamine and a corticosteroid directly to the nasal passages.
The label excerpt provides a mechanism of action for olopatadine and anti-inflammatory activity for mometasone furoate, but does not explicitly state this delivery mechanism/combined direct nasal delivery wording.
Ryaltris targets both the immediate and inflammatory aspects of allergic rhinitis.
The label excerpt does not explicitly describe targeting "immediate" vs "inflammatory" aspects.
Ryaltris provides relief from symptoms such as sneezing, runny nose, nasal itching, and itchy/watery eyes.
The provided label excerpts do not list specific symptom types (e.g., sneezing/runny nose/itchy/watery eyes).
Common side effects reported with Ryaltris include nosebleeds.
Epistaxis is described as observed in 1% vs 0.6% in placebo in 2-week studies, but the label excerpts do not support the blanket phrasing "common side effects" as a category without frequency thresholds. (Still, epistaxis itself is label-supported; the specific characterization is not directly supported.)
Common side effects reported with Ryaltris include conjunctival hyperemia (redness of the eye).
The provided label excerpts mention epistaxis and nasal discomfort among adverse reactions but do not provide conjunctival hyperemia as a reported adverse reaction.
Common side effects reported with Ryaltris include altered taste sensation.
The provided label excerpts do not mention altered taste sensation.
Contradictions
Low
AI Statement
Ryaltris is a prescription nasal spray that combines the antihistamine olopatadine and the corticosteroid fluticasone propionate.
Label Reference
Provided label excerpts list corticosteroid as mometasone furoate (dose: "50 mcg of mometasone furoate").
Low
AI Statement
The active ingredients in Ryaltris are olopatadine hydrochloride and fluticasone propionate.
Label Reference
Provided label excerpts: "2 sprays deliver a total of ... olopatadine hydrochloride and 50 mcg of mometasone furoate."
Low
AI Statement
Ryaltris is indicated for the relief of nasal and ocular symptoms of perennial allergic rhinitis (PAR).
Label Reference
Provided label excerpt for indications: treatment of symptoms of seasonal allergic rhinitis in patients 12 years and older; no perennial allergic rhinitis indication in supplied excerpts.
Important Omissions
Dosage and administration details (e.g., 2 sprays per nostril twice daily; total delivered mcg amounts) were not provided by the AI claims list.
Importance:
Moderate
Contraindication wording (hypersensitivity to ingredients) was not addressed.
Importance:
Moderate
Key warnings relevant to safety such as epistaxis frequency, nasal ulceration/septal perforation precautions, Candida infection risk, somnolence/avoid hazardous occupations, glaucoma/cataracts monitoring, hypersensitivity reaction instructions, infection immunosuppression caution, and pediatric growth monitoring were not systematically covered (only partial adverse reaction claims were made).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Incorrect ingredient identification (fluticasone vs mometasone) and incorrect indication scope (perennial allergic rhinitis) could mislead prescribing and patient expectations; additional adverse reaction assertions (altered taste sensation, conjunctival hyperemia) are not supported by provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Major Misalignment
Primary Issue
Multiple material inaccuracies vs supplied label excerpts, especially active ingredient (fluticasone vs mometasone) and indication (perennial allergic rhinitis not supported).
Suggested Improvement
Replace fluticasone-related statements with mometasone furoate per label excerpts, restrict indication to seasonal allergic rhinitis symptoms as stated, and avoid unsupported symptom/adverse reaction lists unless explicitly supported by the provided label text.